By Amara Osei

The UK government has warned livestock owners, dealers and veterinarians against buying or selling second-hand bluetongue vaccines, flagging the risk that redistributed doses fall outside the regulated supply chain and may be ineffective, mishandled or unsafe.

The alert, posted on GOV.UK, targets informal resale of leftover doses of vaccine against bluetongue virus. The notice does not name specific sellers or platforms, but instructs buyers to obtain vaccine only through authorized veterinary surgeons and registered suppliers.

What's the regulatory hook?

Bluetongue vaccines are prescription-only veterinary medicines in the UK, overseen by the Veterinary Medicines Directorate (VMD). Each batch carries a unique identifier under the Veterinary Medicines Regulations, and any transfer outside the recorded supply chain is a breach of those rules. The VMD can investigate unauthorized supply, with potential enforcement action against individuals and businesses.

The warning closes a known gap in practice. Farmers who vaccinated early in a season sometimes hold unused doses, and informal resale has appeared on classified sites and at livestock markets. Once a dose leaves the qualified-person supply chain, cold-chain integrity and sterility cannot be verified.

A dose that spent two hours unrefrigerated in a car boot, then changed hands twice before reaching a third holding, is a dose the regulator cannot trace. Even when the product itself is genuine, the chain of custody has been broken.

What changes at the farm gate?

• Producers should source vaccine only from their veterinarian or a VMD-registered supplier, even when a second-hand price is lower.
• Veterinarians dispensing bluetongue vaccine should record batch numbers, expiry dates and the destination holding, and remind clients that resale of leftover doses is not permitted.
• Market operators and hauliers should refuse to facilitate private sales of leftover vaccine, and report offers to the VMD.

What's the disease backdrop?

Bluetongue is a notifiable viral disease of cattle, sheep, goats and deer, transmitted by Culicoides midges. Clinical signs range from subclinical infection in cattle to fever, lameness, oedema and oral lesions in sheep, with mortality reaching double digits in naïve flocks.

The UK has been managing an outbreak of serotype 3 (BTV-3) in recent years, with voluntary vaccination programmes in affected English regions and a continuing push to extend coverage before the next vector season.

The species split matters. Cattle are largely amplification hosts, often seroconverting without obvious signs, while sheep show the classic clinical picture and the highest mortality. A single diverted cattle dose, given to the wrong species at the wrong time, can erode a regional control plan more than its unit price suggests.

The case for tighter vaccine stewardship rests on three practical risks. Mishandled doses can lose potency, leaving flocks unprotected during a transmission window. Any adverse reaction from a diverted dose falls outside the VMD pharmacovigilance system, so a genuine safety signal can be lost. And the trade can pull vaccine away from holdings that need it most, complicating regional control.

Where can vets and farmers report concerns?

The GOV.UK notice directs readers to report suspected unauthorized supply to the VMD and to contact the Animal and Plant Health Agency (APHA) for bluetongue-related queries. Practitioners should expect follow-up enforcement messaging as the next vector season builds, and clients who are offered discounted vaccine at market should be steered back to their vet for any bluetongue decisions.